Science
Our unique dual-targeted approach leverages an innovative proprietary platform to optimize the function of natural killer cells, thus maximizing cancer cell killing.
Partnering
We are interested in working with innovative industry partners and academic centers of excellence to progress the science and understanding of natural killer cells.
Latest News
- ONK Therapeutics Appoints Mary Reilly as Chief Operating Officer 18 January 2021
- ONK Therapeutics Appoints Hugh O’Dowd as Independent Chairman 14 January 2021
Careers
We are building a disciplined approach, an exciting team culture and a strong focus on operational excellence in all we do. As we are rapidly expand the company, we are looking for dedicated professionals to join our team and help drive progress in this evolving arena of medicine.
